|Bid||0.0000 x 21500|
|Ask||0.0000 x 45100|
|Day's Range||2.5200 - 2.6750|
|52 Week Range||2.0900 - 11.9200|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.57|
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, July 27, 2021--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.
SAN DIEGO, July 26, 2021--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ:AKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the ti